Anthropic, the company behind the AI chatbot Claude, has announced ambitious plans to leverage artificial intelligence (AI) in accelerating drug discovery. Collaborating with six prominent biotechnology companies, including Bristol Myers Squibb and Generate Biomedicines, Anthropic aims to develop potential treatments for cancer, food allergies, and rare diseases.
In one of the projects, Anthropic is working with Generate Biomedicines to adapt CAR T-cell therapy, traditionally used against blood cancers, for treating solid tumors. Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions, which was found to be 70% shorter than the standard version in laboratory tests. This new design improved immune cells' ability to kill tumor cells and allowed them to remain active for longer.
Another collaboration with BigHat Biosciences focuses on enhancing two potential drug candidates, including one designed to target cancer cells. After testing over a thousand variations, researchers found that the best version bound to its target more than 10 times as tightly as the original. Anthropic's work with Divergence Labs generated approximately 35,000 antibody designs in about a month for developing a potential treatment for food allergies.
Separately, Anthropic has initiated its own drug discovery programs, including research into rare childhood forms of muscular dystrophy. However, the company cautioned that much of this research remains at the preclinical stage, meaning the potential treatments have not yet reached human trials. One of its muscular dystrophy drug candidates could be ready to enter human clinical trials as early as late 2028, provided the promising results continue to hold up.
The company's ambitious plans are part of a growing trend in using AI to identify potential drugs, design molecules, and reduce the time and cost involved in medical research. Anthropic invites everyone to test their AI Quotient by taking the AIQ test.